↓ Skip to main content

Development and validation of longitudinal c-reactive protein as dynamic response predictor for PD-L1 blockade in advanced NSCLC: Findings from four atezolizumab clinical trials.

Overview of attention for article published in Journal of Clinical Oncology, June 2022
Altmetric Badge

Mentioned by

1 X user

Readers on

7 Mendeley